# Study for AZD4360 in Participants With Advanced Solid Tumours

> **NCT06921928** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 117 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Cancer
- Biliary Tract Cancer
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** AZD4360

## Key facts

- **NCT ID:** NCT06921928
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-16
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06921928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06921928, "Study for AZD4360 in Participants With Advanced Solid Tumours". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06921928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*